There is no known antidote for overdoses of TYKERB. The maximum oral doses of lapatinib that have been administered in clinical trials are 1,800 mg once daily. More frequent ingestion of TYKERB could result in serum concentrations exceeding those observed in clinical trials and could result in increased toxicity. Therefore, missed doses should not be replaced and dosing should resume with the next scheduled daily dose.
Asymptomatic and symptomatic cases of overdose have been reported. The doses ranged from 2,500 to 9,000 mg daily and where reported, the duration varied between 1 and 17 days. Symptoms observed include lapatinib-associated events and in some cases sore scalp, sinus tachycardia (with otherwise normal ECG), and/or mucosal inflammation.
Because lapatinib is not significantly renally excreted and is highly bound to plasma proteins, hemodialysis would not be expected to be an effective method to enhance the elimination of lapatinib.
Treatment of overdose with TYKERB should consist of general supportive measures.
TYKERB is contraindicated in patients with known severe hypersensitivity (e.g., anaphylaxis) to this product or any of its components.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
HER2-Positive Metastatic Breast CancerThe safety of TYKERB has been evaluated in more than 12,000 patients in clinical trials. The efficacy and safety of TYKERB in combination with capecitabine in breast cancer was evaluated in 198 patients in a randomized, Phase 3 trial. Adverse reactions which occurred in at least 10% of patients in either treatment arm and were higher in the combination arm are shown in Table 1.
The most common adverse reactions (greater than 20%) during therapy with TYKERB plus capecitabine were gastrointestinal (diarrhea, nausea, and vomiting), dermatologic (palmar-plantar erythrodysesthesia and rash), and fatigue. Diarrhea was the most common adverse reaction resulting in discontinuation of study medication.
The most common Grade 3 and 4 adverse reactions (NCI CTCAE v3) were diarrhea and palmar-plantar erythrodysesthesia. Selected laboratory abnormalities are shown in Table 2.
Table 1. Adverse Reactions Occurring in Greater Than or Equal to 10% of Patients
| Reactions | TYKERB 1,250 mg/day + Capecitabine 2,000 mg/m2/day (N = 198) |
Capecitabine 2,500 mg/m2/day (N = 191) |
||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| % | % | % | % | % | % | |
| Gastrointestinal disorders | ||||||
| Diarrhea | 65 | 13 | 1 | 40 | 10 | 0 |
| Nausea | 44 | 2 | 0 | 43 | 2 | 0 |
| Vomiting | 26 | 2 | 0 | 21 | 2 | 0 |
| Stomatitis | 14 | 0 | 0 | 11 | <1 | 0 |
| Dyspepsia | 11 | <1 | 0 | 3 | 0 | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Palmar-plantar erythrodysesthesia | 53 | 12 | 0 | 51 | 14 | 0 |
| Rashb | 28 | 2 | 0 | 14 | 1 | 0 |
| Dry skin | 10 | 0 | 0 | 6 | 0 | 0 |
| General disorders and administrative site conditions | ||||||
| Mucosal inflammation | 15 | 0 | 0 | 12 | 2 | 0 |
| Musculoskeletal and connective tissue disorders | ||||||
| Pain in extremity | 12 | 1 | 0 | 7 | <1 | 0 |
| Back pain | 11 | 1 | 0 | 6 | <1 | 0 |
| Respiratory, thoracic, and mediastinal disorders | ||||||
| Dyspnea | 12 | 3 | 0 | 8 | 2 | 0 |
| Psychiatric disorders | ||||||
| Insomnia | 10 | <1 | 0 | 6 | 0 | 0 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. b Grade 3 dermatitis acneiform was reported in less than 1% of patients in the group receiving TYKERB plus capecitabine. |
||||||
Table 2. Selected Laboratory Abnormalities
| TYKERB 1,250 mg/day + Capecitabine 2,000 mg/m2/day | Capecitabine 2,500 mg/m2/day | |||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| Parameters | % | % | % | % | % | % |
| Hematologic | ||||||
| Hemoglobin | 56 | <1 | 0 | 53 | 1 | 0 |
| Platelets | 18 | <1 | 0 | 17 | <1 | <1 |
| Neutrophils | 22 | 3 | <1 | 31 | 2 | 1 |
| Hepatic | ||||||
| Total Bilirubin | 45 | 4 | 0 | 30 | 3 | 0 |
| AST | 49 | 2 | <1 | 43 | 2 | 0 |
| ALT | 37 | 2 | 0 | 33 | 1 | 0 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. | ||||||
In a randomized clinical trial of patients (N = 1,286) with hormone receptor-positive, metastatic breast cancer, who had not received chemotherapy for their metastatic disease, patients received letrozole with or without TYKERB. In this trial, the safety profile of TYKERB was consistent with previously reported results from trials of TYKERB in the advanced or metastatic breast cancer population. Adverse reactions which occurred in at least 10% of patients in either treatment arm and were higher in the combination arm are shown in Table 3. Selected laboratory abnormalities are shown in Table 4.
Table 3. Adverse Reactions Occurring in Greater Than or Equal to 10% of Patients
| Reactions | TYKERB 1,500 mg/day + Letrozole 2.5 mg/day (N = 654) |
Letrozole 2.5 mg/day (N = 624) |
||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| % | % | % | % | % | % | |
| Gastrointestinal disorders | ||||||
| Diarrhea | 64 | 9 | <1 | 20 | <1 | 0 |
| Nausea | 31 | <1 | 0 | 21 | <1 | 0 |
| Vomiting | 17 | 1 | <1 | 11 | <1 | <1 |
| Anorexia | 11 | <1 | 0 | 9 | <1 | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Rashb | 44 | 1 | 0 | 13 | 0 | 0 |
| Dry skin | 13 | <1 | 0 | 4 | 0 | 0 |
| Alopecia | 13 | <1 | 0 | 7 | 0 | 0 |
| Pruritus | 12 | <1 | 0 | 9 | <1 | 0 |
| Nail Disorder | 11 | <1 | 0 | <1 | 0 | 0 |
| General disorders and administrative site conditions | ||||||
| Fatigue | 20 | 2 | 0 | 17 | <1 | 0 |
| Asthenia | 12 | <1 | 0 | 11 | <1 | 0 |
| Nervous system disorders | ||||||
| Headache | 14 | <1 | 0 | 13 | <1 | 0 |
| Respiratory, thoracic, and mediastinal disorders | ||||||
| Epistaxis | 11 | <1 | 0 | 2 | <1 | 0 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. b In addition to the rash reported under "Skin and subcutaneous tissue disorders", 3 additional subjects in each treatment arm had rash under "Infections and infestations"; none were Grade 3 or 4. |
||||||
Table 4. Selected Laboratory Abnormalities
| TYKERB 1,500 mg/day + Letrozole 2.5 mg/day | Letrozole 2.5 mg/day | |||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| Hepatic Parameters | % | % | % | % | % | % |
| AST | 53 | 6 | 0 | 36 | 2 | <1 |
| ALT | 46 | 5 | <1 | 35 | 1 | 0 |
| Total Bilirubin | 22 | <1 | <1 | 11 | 1 | <1 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. |
Due to potential cardiac toxicity with HER2 (ErbB2) inhibitors, LVEF was monitored in clinical trials at approximately 8-week intervals. LVEF decreases were defined as signs or symptoms of deterioration in left ventricular cardiac function that are greater than or equal to Grade 3 (NCI CTCAE), or a greater than or equal to 20% decrease in left ventricular cardiac ejection fraction relative to baseline which is below the institution's lower limit of normal. Among 198 patients who received combination treatment with TYKERB/capecitabine, 3 experienced Grade 2 and one had Grade 3 LVEF adverse reactions (NCI CTCAE v3). Among 654 patients who received combination treatment with TYKERB/letrozole, 26 patients experienced Grade 1 or 2 and 6 patients had Grade 3 or 4 LVEF adverse reactions.
HepatotoxicityTYKERB has been associated with hepatotoxicity.
Interstitial Lung Disease/PneumonitisTYKERB has been associated with interstitial lung disease and pneumonitis in monotherapy or in combination with other chemotherapies.
Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of TYKERB. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune System Disorders: Hypersensitivity reactions including anaphylaxis.
Skin and Subcutaneous Tissue Disorders: Nail disorders including paronychia. Severe cutaneous adverse reactions including Stevens Johnson Syndrome (SJS) and toxic epidural necrolysis (TEN).
Cardiac Disorders: Ventricular arrhythmias/Torsades de Points (TdP). Electrocardiogram QT prolongation.
TYKERB® is indicated in combination with:
TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
Absorption following oral administration of TYKERB is incomplete and variable. Serum concentrations appear after a median lag time of 0.25 hours (range 0 to 1.5 hours). Peak plasma concentrations (Cmax) of lapatinib are achieved approximately 4 hours after administration. Daily dosing of TYKERB results in achievement of steady state within 6 to 7 days, indicating an effective half-life of 24 hours.
At the dose of 1,250 mg daily, steady-state geometric mean [95% confidence interval (CI)] values of Cmax were 2.43 mcg/mL (1.57 to 3.77 mcg/mL) and AUC were 36.2 mcg.h/mL (23.4 to 56 mcg.h/mL).
Divided daily doses of TYKERB resulted in approximately 2-fold higher exposure at steady state (steady-state AUC) compared to the same total dose administered once daily.
Systemic exposure to lapatinib is increased when administered with food. Lapatinib AUC values were approximately 3- and 4-fold higher (Cmax approximately 2.5- and 3-fold higher) when administered with a low-fat (5% fat-500 calories) or with a high-fat (50% fat-1,000 calories) meal, respectively.
DistributionLapatinib is highly bound (greater than 99%) to albumin and alpha-1 acid glycoprotein. In vitro studies indicate that lapatinib is a substrate for the transporters breast cancer-resistance protein (BCRP, ABCG2) and P-glycoprotein (P-gp, ABCB1). Lapatinib has also been shown to inhibit P-gp, BCRP, and the hepatic uptake transporter OATP 1B1, in vitro at clinically relevant concentrations.
MetabolismLapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 10% of lapatinib concentration in plasma.
EliminationAt clinical doses, the terminal phase half-life following a single dose was 14.2 hours; accumulation with repeated dosing indicates an effective half-life of 24 hours.
Elimination of lapatinib is predominantly through metabolism by CYP3A4/5 with negligible (less than 2%) renal excretion. Recovery of parent lapatinib in feces accounts for a median of 27% (range 3% to 67%) of an oral dose.
Effects Of Age, Gender, Or RaceStudies of the effects of age, gender, or race on the pharmacokinetics of lapatinib have not been performed.
Based on findings in animals, TYKERB can cause fetal harm when administered to a pregnant woman. Lapatinib administered to rats during organogenesis and through lactation led to death of offspring within the first 4 days after birth. When administered to pregnant animals during the period of organogenesis, lapatinib caused fetal anomalies (rats) or abortions (rabbits) at maternally toxic doses. There are no adequate and well-controlled studies with TYKERB in pregnant women. Women should be advised not to become pregnant when taking TYKERB. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
In a study where pregnant rats were dosed with lapatinib during organogenesis and through lactation, at a dose of 120 mg/kg/day (approximately 6.4 times the human clinical exposure based on AUC following 1,250-mg dose of lapatinib plus capecitabine), 91% of the pups had died by the fourth day after birth, while 34% of the 60 mg/kg/day pups were dead. The highest no-effect dose for this study was 20 mg/kg/day (approximately equal to the human clinical exposure based on AUC).
Lapatinib was studied for effects on embryo-fetal development in pregnant rats and rabbits given oral doses of 30, 60, and 120 mg/kg/day. There were no teratogenic effects; however, minor anomalies (left-sided umbilical artery, cervical rib, and precocious ossification) occurred in rats at the maternally toxic dose of 120 mg/kg/day (approximately 6.4 times the human clinical exposure based on AUC following 1,250-mg dose of lapatinib plus capecitabine). In rabbits, lapatinib was associated with maternal toxicity at 60 and 120 mg/kg/day (approximately 0.07 and 0.2 times the human clinical exposure, respectively, based on AUC following 1,250mg dose of lapatinib plus capecitabine) and abortions at 120 mg/kg/day. Maternal toxicity was associated with decreased fetal body weights and minor skeletal variations.
250 mg tablets — oval, biconvex, orange, film-coated with GS XJG debossed on one side.
Storage And HandlingThe 250 mg tablets of TYKERB are oval, biconvex, orange, and film-coated with GS XJG debossed on one side and are available in:
Bottles of 150 tablets: NDC 0078-0671-19
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936. Revised: April 2017
Included as part of the "PRECAUTIONS" Section
PRECAUTIONS Decreased Left Ventricular Ejection FractionTYKERB has been reported to decrease LVEF. In clinical trials, the majority (greater than 57%) of LVEF decreases occurred within the first 12 weeks of treatment; however, data on long-term exposure are limited. Caution should be taken if TYKERB is to be administered to patients with conditions that could impair left ventricular function. LVEF should be evaluated in all patients prior to initiation of treatment with TYKERB to ensure that the patient has a baseline LVEF that is within the institution's normal limits. LVEF should continue to be evaluated during treatment with TYKERB to ensure that LVEF does not decline below the institution's normal limits.
HepatotoxicityHepatotoxicity (ALT or AST greater than 3 times the upper limit of normal and total bilirubin greater than 2 times the upper limit of normal) has been observed in clinical trials (less than 1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with TYKERB should be discontinued and patients should not be retreated with TYKERB.
Patients With Severe Hepatic ImpairmentIf TYKERB is to be administered to patients with severe preexisting hepatic impairment, dose reduction should be considered. In patients who develop severe hepatotoxicity while on therapy, TYKERB should be discontinued and patients should not be retreated with TYKERB.
DiarrheaDiarrhea has been reported during treatment with TYKERB. The diarrhea may be severe, and deaths have been reported. Diarrhea generally occurs early during treatment with TYKERB, with almost half of those patients with diarrhea first experiencing it within 6 days. This usually lasts 4 to 5 days. Lapatinib-induced diarrhea is usually low-grade, with severe diarrhea of NCI CTCAE Grades 3 and 4 occurring in less than 10% and less than 1% of patients, respectively. Early identification and intervention is critical for the optimal management of diarrhea. Patients should be instructed to report any change in bowel patterns immediately. Prompt treatment of diarrhea with antidiarrheal agents (such as loperamide) after the first unformed stool is recommended. Severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids, use of antibiotics such as fluoroquinolones (especially if diarrhea is persistent beyond 24 hours, there is fever, or Grade 3 or 4 neutropenia), and interruption or discontinuation of therapy with TYKERB.
Interstitial Lung Disease/PneumonitisLapatinib has been associated with interstitial lung disease and pneumonitis in monotherapy or in combination with other chemotherapies. Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease or pneumonitis. TYKERB should be discontinued in patients who experience pulmonary symptoms indicative of interstitial lung disease/pneumonitis which are greater than or equal to Grade 3 (NCI CTCAE).
QT ProlongationQT prolongation was observed in an uncontrolled, open-label, dose-escalation study of lapatinib in advanced cancer patients. Lapatinib should be administered with caution to patients who have or may develop prolongation of QTc. These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy. Hypokalemia or hypomagnesemia should be corrected prior to lapatinib administration.
Severe Cutaneous ReactionsSevere cutaneous reactions have been reported with TYKERB. If life-threatening reactions such as erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis (e.g., progressive skin rash often with blisters or mucosal lesions) are suspected, discontinue treatment with TYKERB.
Use In PregnancyTYKERB can cause fetal harm when administered to a pregnant woman. Based on findings in animals, TYKERB is expected to result in adverse reproductive effects. Lapatinib administered to rats during organogenesis and through lactation led to death of offspring within the first 4 days after birth.
There are no adequate and well-controlled studies with TYKERB in pregnant women. Women should be advised not to become pregnant when taking TYKERB. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Patient Counseling InformationAdvise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Patients should be informed of the following:
In carcinogenicity studies, lapatinib was administered orally for up to 104 weeks at doses of 75 and 150 mg/kg/day in male mice and 75, 150, and 300 mg/kg/day in female mice (approximately 0.7 to 2 times the expected human clinical exposure based on AUC for a clinical dose of 1,250 mg/day) and 60, 120, 240, and 500 mg/kg/day (approximately 0.6 to 2.3 times the expected human clinical exposure based on AUC) in male rats, and 20, 60, and 180 mg/kg/day (approximately 1.4 to 10 times the expected human clinical exposure based on AUC) in female rats. There was no evidence of carcinogenicity in mice. In male rats, there was an increased incidence of whole body combined hemangiomas and hemangiosarcomas.
Lapatinib was not clastogenic or mutagenic in the Chinese hamster ovary chromosome aberration assay, microbial mutagenesis (Ames) assay, human lymphocyte chromosome aberration assay or the in vivo rat bone marrow chromosome aberration assay at single doses up to 2,000 mg/kg. However, an impurity in the drug product (up to 4 ppm or 8 mcg/day) was genotoxic when tested alone in both in vitro and in vivo assays.
There were no effects on male or female rat mating or fertility at doses up to 120 mg/kg/day in females and 180 mg/kg/day in males (approximately 6.4 times and 2.6 times the expected human clinical exposure based on AUC following 1,250-mg dose of lapatinib plus capecitabine, respectively). The effect of lapatinib on human fertility is unknown. However, when female rats were given oral doses of lapatinib during breeding and through the first 6 days of gestation, a significant decrease in the number of live fetuses was seen at 120 mg/kg/day and in the fetal body weights at greater than or equal to 60 mg/kg/day (approximately 6.4 times and 3.3 times the expected human clinical exposure based on AUC following 1,250-mg dose of lapatinib plus capecitabine, respectively).
Use In Specific Populations Pregnancy Pregnancy Category DBased on findings in animals, TYKERB can cause fetal harm when administered to a pregnant woman. Lapatinib administered to rats during organogenesis and through lactation led to death of offspring within the first 4 days after birth. When administered to pregnant animals during the period of organogenesis, lapatinib caused fetal anomalies (rats) or abortions (rabbits) at maternally toxic doses. There are no adequate and well-controlled studies with TYKERB in pregnant women. Women should be advised not to become pregnant when taking TYKERB. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
In a study where pregnant rats were dosed with lapatinib during organogenesis and through lactation, at a dose of 120 mg/kg/day (approximately 6.4 times the human clinical exposure based on AUC following 1,250-mg dose of lapatinib plus capecitabine), 91% of the pups had died by the fourth day after birth, while 34% of the 60 mg/kg/day pups were dead. The highest no-effect dose for this study was 20 mg/kg/day (approximately equal to the human clinical exposure based on AUC).
Lapatinib was studied for effects on embryo-fetal development in pregnant rats and rabbits given oral doses of 30, 60, and 120 mg/kg/day. There were no teratogenic effects; however, minor anomalies (left-sided umbilical artery, cervical rib, and precocious ossification) occurred in rats at the maternally toxic dose of 120 mg/kg/day (approximately 6.4 times the human clinical exposure based on AUC following 1,250-mg dose of lapatinib plus capecitabine). In rabbits, lapatinib was associated with maternal toxicity at 60 and 120 mg/kg/day (approximately 0.07 and 0.2 times the human clinical exposure, respectively, based on AUC following 1,250mg dose of lapatinib plus capecitabine) and abortions at 120 mg/kg/day. Maternal toxicity was associated with decreased fetal body weights and minor skeletal variations.
Nursing MothersIt is not known whether lapatinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from TYKERB, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric UseThe safety and effectiveness of TYKERB in pediatric patients have not been established.
Geriatric UseOf the total number of metastatic breast cancer patients in clinical studies of TYKERB in combination with capecitabine (N = 198), 17% were 65 years of age and older, and 1% were 75 years of age and older. Of the total number of hormone receptor-positive, HER2-positive metastatic breast cancer patients in clinical studies of TYKERB in combination with letrozole (N = 642), 44% were 65 years of age and older, and 12% were 75 years of age and older. No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Renal ImpairmentLapatinib pharmacokinetics have not been specifically studied in patients with renal impairment or in patients undergoing hemodialysis. There is no experience with TYKERB in patients with severe renal impairment. However, renal impairment is unlikely to affect the pharmacokinetics of lapatinib given that less than 2% (lapatinib and metabolites) of an administered dose is eliminated by the kidneys.
Hepatic ImpairmentThe pharmacokinetics of lapatinib were examined in subjects with preexisting moderate (n = 8) or severe (n = 4) hepatic impairment (Child-Pugh Class B/C, respectively) and in 8 healthy control subjects. Systemic exposure (AUC) to lapatinib after a single oral 100-mg dose increased approximately 14% and 63% in subjects with moderate and severe preexisting hepatic impairment, respectively. Administration of TYKERB in patients with severe hepatic impairment should be undertaken with caution due to increased exposure to the drug. A dose reduction should be considered for patients with severe preexisting hepatic impairment. In patients who develop severe hepatotoxicity while on therapy, TYKERB should be discontinued and patients should not be retreated with TYKERB.
The recommended dose of TYKERB is 1,250 mg given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21-day cycle. TYKERB should be taken at least one hour before or one hour after a meal. The dose of TYKERB should be once daily (5 tablets administered all at once); dividing the daily dose is not recommended. Capecitabine should be taken with food or within 30 minutes after food. If a day's dose is missed, the patient should not double the dose the next day. Treatment should be continued until disease progression or unacceptable toxicity occurs.
Hormone Receptor-Positive, HER2-Positive Metastatic Breast CancerThe recommended dose of TYKERB is 1,500 mg given orally once daily continuously in combination with letrozole. When coadministered with TYKERB, the recommended dose of letrozole is 2.5 mg once daily. TYKERB should be taken at least one hour before or one hour after a meal. The dose of TYKERB should be once daily (6 tablets administered all at once); dividing the daily dose is not recommended.
Dose Modification Guidelines Cardiac EventsTYKERB should be discontinued in patients with a decreased left ventricular ejection fraction (LVEF) that is Grade 2 or greater by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3), and in patients with an LVEF that drops below the institution's lower limit of normal (LLN). TYKERB in combination with capecitabine may be restarted at a reduced dose (1,000 mg/day) and in combination with letrozole may be restarted at a reduced dose of 1,250 mg/day after a minimum of 2 weeks if the LVEF recovers to normal and the patient is asymptomatic.
Hepatic ImpairmentPatients with severe hepatic impairment (Child-Pugh Class C) should have their dose of TYKERB reduced. A dose reduction from 1,250 mg/day to 750 mg/day (HER2-positive metastatic breast cancer indication) or from 1,500 mg/day to 1,000 mg/day (hormone receptor-positive, HER2-positive breast cancer indication) in patients with severe hepatic impairment is predicted to adjust the area under the curve (AUC) to the normal range and should be considered. However, there are no clinical data with this dose adjustment in patients with severe hepatic impairment.
DiarrheaTYKERB should be interrupted in patients with diarrhea which is NCI CTCAE Grade 3 or Grade 1 or 2 with complicating features (moderate to severe abdominal cramping, nausea or vomiting greater than or equal to NCI CTCAE Grade 2, decreased performance status, fever, sepsis, neutropenia, frank bleeding, or dehydration). TYKERB may be reintroduced at a lower dose (reduced from 1,250 mg/day to 1,000 mg/day or from 1,500 mg/day to 1,250 mg/day) when diarrhea resolves to Grade 1 or less. TYKERB should be permanently discontinued in patients with diarrhea which is NCI CTCAE Grade 4.
Concomitant Strong CYP3A4 InhibitorsThe concomitant use of strong CYP3A4 inhibitors should be avoided (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole). Grapefruit may also increase plasma concentrations of lapatinib and should be avoided. If patients must be coadministered, a strong CYP3A4 inhibitor, based on pharmacokinetic studies, a dose reduction to 500 mg/day of lapatinib is predicted to adjust the lapatinib AUC to the range observed without inhibitors and should be considered. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inhibitors. If the strong inhibitor is discontinued, a washout period of approximately 1 week should be allowed before the lapatinib dose is adjusted upward to the indicated dose.
Concomitant Strong CYP3A4 InducersThe concomitant use of strong CYP3A4 inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's wort). If patients must be coadministered a strong CYP3A4 inducer, based on pharmacokinetic studies, the dose of lapatinib should be titrated gradually from 1,250 mg/day up to 4,500 mg/day (HER2-positive metastatic breast cancer indication) or from 1,500 mg/day up to 5,500 mg/day (hormone receptor-positive, HER2-positive breast cancer indication) based on tolerability. This dose of lapatinib is predicted to adjust the lapatinib AUC to the range observed without inducers and should be considered. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inducers. If the strong inducer is discontinued the lapatinib dose should be reduced to the indicated dose.
Other ToxicitiesDiscontinuation or interruption of dosing with TYKERB may be considered when patients develop greater than or equal to Grade 2 NCI CTCAE toxicity and can be restarted at the standard dose of 1,250 or 1,500 mg/day when the toxicity improves to Grade 1 or less. If the toxicity recurs, then TYKERB in combination with capecitabine should be restarted at a lower dose (1,000 mg/day) and in combination with letrozole should be restarted at a lower dose of 1,250 mg/day.
See manufacturer’s prescribing information for the coadministered product dosage adjustment guidelines in the event of toxicity and other relevant safety information or contraindications.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
HER2-Positive Metastatic Breast CancerThe safety of TYKERB has been evaluated in more than 12,000 patients in clinical trials. The efficacy and safety of TYKERB in combination with capecitabine in breast cancer was evaluated in 198 patients in a randomized, Phase 3 trial. Adverse reactions which occurred in at least 10% of patients in either treatment arm and were higher in the combination arm are shown in Table 1.
The most common adverse reactions (greater than 20%) during therapy with TYKERB plus capecitabine were gastrointestinal (diarrhea, nausea, and vomiting), dermatologic (palmar-plantar erythrodysesthesia and rash), and fatigue. Diarrhea was the most common adverse reaction resulting in discontinuation of study medication.
The most common Grade 3 and 4 adverse reactions (NCI CTCAE v3) were diarrhea and palmar-plantar erythrodysesthesia. Selected laboratory abnormalities are shown in Table 2.
Table 1. Adverse Reactions Occurring in Greater Than or Equal to 10% of Patients
| Reactions | TYKERB 1,250 mg/day + Capecitabine 2,000 mg/m2/day (N = 198) |
Capecitabine 2,500 mg/m2/day (N = 191) |
||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| % | % | % | % | % | % | |
| Gastrointestinal disorders | ||||||
| Diarrhea | 65 | 13 | 1 | 40 | 10 | 0 |
| Nausea | 44 | 2 | 0 | 43 | 2 | 0 |
| Vomiting | 26 | 2 | 0 | 21 | 2 | 0 |
| Stomatitis | 14 | 0 | 0 | 11 | <1 | 0 |
| Dyspepsia | 11 | <1 | 0 | 3 | 0 | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Palmar-plantar erythrodysesthesia | 53 | 12 | 0 | 51 | 14 | 0 |
| Rashb | 28 | 2 | 0 | 14 | 1 | 0 |
| Dry skin | 10 | 0 | 0 | 6 | 0 | 0 |
| General disorders and administrative site conditions | ||||||
| Mucosal inflammation | 15 | 0 | 0 | 12 | 2 | 0 |
| Musculoskeletal and connective tissue disorders | ||||||
| Pain in extremity | 12 | 1 | 0 | 7 | <1 | 0 |
| Back pain | 11 | 1 | 0 | 6 | <1 | 0 |
| Respiratory, thoracic, and mediastinal disorders | ||||||
| Dyspnea | 12 | 3 | 0 | 8 | 2 | 0 |
| Psychiatric disorders | ||||||
| Insomnia | 10 | <1 | 0 | 6 | 0 | 0 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. b Grade 3 dermatitis acneiform was reported in less than 1% of patients in the group receiving TYKERB plus capecitabine. |
||||||
Table 2. Selected Laboratory Abnormalities
| TYKERB 1,250 mg/day + Capecitabine 2,000 mg/m2/day | Capecitabine 2,500 mg/m2/day | |||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| Parameters | % | % | % | % | % | % |
| Hematologic | ||||||
| Hemoglobin | 56 | <1 | 0 | 53 | 1 | 0 |
| Platelets | 18 | <1 | 0 | 17 | <1 | <1 |
| Neutrophils | 22 | 3 | <1 | 31 | 2 | 1 |
| Hepatic | ||||||
| Total Bilirubin | 45 | 4 | 0 | 30 | 3 | 0 |
| AST | 49 | 2 | <1 | 43 | 2 | 0 |
| ALT | 37 | 2 | 0 | 33 | 1 | 0 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. | ||||||
In a randomized clinical trial of patients (N = 1,286) with hormone receptor-positive, metastatic breast cancer, who had not received chemotherapy for their metastatic disease, patients received letrozole with or without TYKERB. In this trial, the safety profile of TYKERB was consistent with previously reported results from trials of TYKERB in the advanced or metastatic breast cancer population. Adverse reactions which occurred in at least 10% of patients in either treatment arm and were higher in the combination arm are shown in Table 3. Selected laboratory abnormalities are shown in Table 4.
Table 3. Adverse Reactions Occurring in Greater Than or Equal to 10% of Patients
| Reactions | TYKERB 1,500 mg/day + Letrozole 2.5 mg/day (N = 654) |
Letrozole 2.5 mg/day (N = 624) |
||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| % | % | % | % | % | % | |
| Gastrointestinal disorders | ||||||
| Diarrhea | 64 | 9 | <1 | 20 | <1 | 0 |
| Nausea | 31 | <1 | 0 | 21 | <1 | 0 |
| Vomiting | 17 | 1 | <1 | 11 | <1 | <1 |
| Anorexia | 11 | <1 | 0 | 9 | <1 | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Rashb | 44 | 1 | 0 | 13 | 0 | 0 |
| Dry skin | 13 | <1 | 0 | 4 | 0 | 0 |
| Alopecia | 13 | <1 | 0 | 7 | 0 | 0 |
| Pruritus | 12 | <1 | 0 | 9 | <1 | 0 |
| Nail Disorder | 11 | <1 | 0 | <1 | 0 | 0 |
| General disorders and administrative site conditions | ||||||
| Fatigue | 20 | 2 | 0 | 17 | <1 | 0 |
| Asthenia | 12 | <1 | 0 | 11 | <1 | 0 |
| Nervous system disorders | ||||||
| Headache | 14 | <1 | 0 | 13 | <1 | 0 |
| Respiratory, thoracic, and mediastinal disorders | ||||||
| Epistaxis | 11 | <1 | 0 | 2 | <1 | 0 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. b In addition to the rash reported under "Skin and subcutaneous tissue disorders", 3 additional subjects in each treatment arm had rash under "Infections and infestations"; none were Grade 3 or 4. |
||||||
Table 4. Selected Laboratory Abnormalities
| TYKERB 1,500 mg/day + Letrozole 2.5 mg/day | Letrozole 2.5 mg/day | |||||
| All Gradesa | Grade 3 | Grade 4 | All Gradesa | Grade 3 | Grade 4 | |
| Hepatic Parameters | % | % | % | % | % | % |
| AST | 53 | 6 | 0 | 36 | 2 | <1 |
| ALT | 46 | 5 | <1 | 35 | 1 | 0 |
| Total Bilirubin | 22 | <1 | <1 | 11 | 1 | <1 |
| a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. |
Due to potential cardiac toxicity with HER2 (ErbB2) inhibitors, LVEF was monitored in clinical trials at approximately 8-week intervals. LVEF decreases were defined as signs or symptoms of deterioration in left ventricular cardiac function that are greater than or equal to Grade 3 (NCI CTCAE), or a greater than or equal to 20% decrease in left ventricular cardiac ejection fraction relative to baseline which is below the institution's lower limit of normal. Among 198 patients who received combination treatment with TYKERB/capecitabine, 3 experienced Grade 2 and one had Grade 3 LVEF adverse reactions (NCI CTCAE v3). Among 654 patients who received combination treatment with TYKERB/letrozole, 26 patients experienced Grade 1 or 2 and 6 patients had Grade 3 or 4 LVEF adverse reactions.
HepatotoxicityTYKERB has been associated with hepatotoxicity.
Interstitial Lung Disease/PneumonitisTYKERB has been associated with interstitial lung disease and pneumonitis in monotherapy or in combination with other chemotherapies.
Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of TYKERB. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune System Disorders: Hypersensitivity reactions including anaphylaxis.
Skin and Subcutaneous Tissue Disorders: Nail disorders including paronychia. Severe cutaneous adverse reactions including Stevens Johnson Syndrome (SJS) and toxic epidural necrolysis (TEN).
Cardiac Disorders: Ventricular arrhythmias/Torsades de Points (TdP). Electrocardiogram QT prolongation.
DRUG INTERACTIONS Effects Of Lapatinib On Drug-Metabolizing Enzymes And Drug Transport SystemsLapatinib inhibits CYP3A4, CYP2C8, and P-glycoprotein (P-gp, ABCB1) in vitro at clinically relevant concentrations and is a weak inhibitor of CYP3A4 in vivo. Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing TYKERB concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4, CYP2C8, or P-gp. Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.
MidazolamFollowing coadministration of TYKERB and midazolam (CYP3A4 substrate), 24-hour systemic exposure (AUC) of orally administered midazolam increased 45%, while 24-hour AUC of intravenously administered midazolam increased 22%.
PaclitaxelIn cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. This increase in paclitaxel exposure may have been underestimated from the in vivo evaluation due to study design limitations.
DigoxinFollowing coadministration of TYKERB and digoxin (P-gp substrate), systemic AUC of an oral digoxin dose increased approximately 2.8-fold. Serum digoxin concentrations should be monitored prior to initiation of TYKERB and throughout coadministration. If digoxin serum concentration is greater than 1.2 ng/mL, the digoxin dose should be reduced by half.
Drugs That Inhibit Or Induce Cytochrome P450 3A4 EnzymesLapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly (see Ketoconazole and Carbamazepine sections, below). Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.
KetoconazoleIn healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
CarbamazepineIn healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
Drugs That Inhibit Drug Transport SystemsLapatinib is a substrate of the efflux transporter P-glycoprotein (P-gp, ABCB1). If TYKERB is administered with drugs that inhibit P-gp, increased concentrations of lapatinib are likely, and caution should be exercised.
Acid-Reducing AgentsThe aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure.
